London, 13 June 2022 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, is pleased to announce the establishment of Hikma France S.A.S. (Hikma France). This marks Hikma’s official entry into France, which has the second largest pharmaceutical market in Europe and a generic injectables hospital market of approximately $2 billion .
13 June 2022
To date, Hikma has supplied 21 generic injectable medicines to hospitals in France through a third-party. Following the approval of Hikma France and the opening of a new commercial office outside Paris, it will now supply medicines to hospitals directly. This broadened portfolio will span several therapeutic areas including anti-infective, cardiovascular and central nervous system.
Hikma has an established and growing presence in Europe with high-quality manufacturing plants in Portugal, Italy and Germany, supplying injectable products to North America, the Middle East and North Africa and Europe.
Riad Mishlawi, President of Hikma Injectables commented:
“The expansion into France is an important step forward in our European growth ambition. Hikma France will complement our existing presence in Europe. I am excited by the opportunity to supply French hospitals and their patients with high-quality and affordable injectable medicines. We look forward to building our presence here as we aim to become a key player in the French hospital market.”